Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q4 2017 call → NOThe question asks whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is already visible. I need to look for a specific, identifiable piece of the company that has been proven out in real operation, and that the company is right now standing up further instances of that same piece in other locations, customers, markets, channels, applications, or lines, where management can already point to demand or commitment waiting for those new instances. Let me review the transcript for any such description. The transcript discusses: - EXPAREL sales growth - J&J partnership - Clinical trials (C-section, hip fracture, spine, colorectal, breast reconstruction) - Manufacturing expansion in the UK - Reimbursement efforts with CMS - Partnerships with healthcare systems (WellStar, ISQIC, CTCA, University of Tennessee) - Pipeline (DepoMeloxicam, DepoTranexamic Acid) The question is specifically about "copying a part of its own business that is already working into additional places where the same demand is already visible." This sounds like it could relate to manufacturing capacity, or perhaps to the J&J partnership model, or to the partnerships with healthcare systems. Let me look at the manufacturing discussion. Dave Stack says: "We have plenty of capacity from our current facilities in San Diego and our online facilities coming late this year in Swindon. We will give Swindon as much material as they can make, because it is an improved gross margin." This is about expanding manufacturing capacity. Is this a proven instance being copied? The San Diego facility is proven, and they are building the UK facility. But is the demand already visible at the destination? The demand is for EXPAREL, which is already being sold. But is this "copying a part of its own business" in the sense of the question? The question seems to be about replicating a proven business unit into new locations where demand is already waiting. Let me think about the J&J partnership. The J&J partnership is being expanded across sales verticals (joint reconstruction, spine, sports, trauma). But is this a "proven instance" being copied? The J&J partnership has been running for a year and is gaining traction. They are now activating accounts across four sales verticals.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.